⚠ Data freshness notice: the most recent refresh of NHTSA was incomplete, so a
very recent recall may be missing. Everything shown is accurate as of the last checked time on this page —
for anything time-critical, confirm with the official sources linked below.
FDAClass II · Drug · Recalled July 8, 2026
Lidocaine HCl Injection USP recall — Asclemed USA Inc.
Hazard: Lack of Assurance of Sterility
Class II: may cause temporary or medically reversible health consequences.
View the official FDA enforcement record (openFDA) ↗
- Official recall ID
- D-0659-2026
- Brand
- Asclemed USA
- Classification
- Class II
- Units affected
- N/A
- Recall status
- Ongoing
- Initiated
- Voluntary: Firm initiated
Description
Lidocaine HCl Injection USP, 1% (10 mg/mL), 5 mL single dose ampule, Rx Only, Distributed by Enovachem Pharmaceuticals, Torrance, CA 90501, NDC: 85766-187-01.
Affected products
Companies & origin
- Recalling firm location
- Torrance, CA, United States
- Firm address
- 379 Van Ness Ave Ste 1403, N/A, 90501-7211
Identifying details (verbatim from the notice)
- Product codes / lots
- Lot #: AE3102, 031926L01, 032026A01, Exp 11/30/2026; AE5052, 052026G01, Exp 04/30/2028.
- Distribution
- USA Nationwide
- Firm notified the public via
- Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
- FDA event ID
- 99204
- Recall initiated
- June 8, 2026
- FDA classified
- July 2, 2026
- FDA report date
- July 8, 2026
Source: U.S. Food & Drug Administration. This page mirrors the official public-domain record verbatim;
the linked government source is authoritative. Source last checked July 23, 2026 at 11:04 PM UTC.
Report a data error on this page